Incretin-based therapies in older adults: current evidence and clinical considerations

Incretin-based therapies have transformed obesity treatment, but evidence in older adults remains limited. Available analyses indicate that weight-loss efficacy is broadly preserved after the age of 65, and no consistent age-specific safety signal has emerged. However, adults aged ≥ 75 years, particularly those with frailty, sarcopenia, malnutrition, or functional impairment, remain underrepresented. Gastrointestinal adverse events may have greater clinical consequences in older adults as reduced intake, dehydration, and medication interactions may compromise physiological reserve. Weight loss also induces loss of lean tissue, although current data do not establish that this routinely translates into sarcopenia or functional decline. Clinical care should focus on net benefit rather than weight reduction alone, incorporating nutritional status, muscle strength, physical function, multimorbidity and polypharmacy. Prospective studies enriched for the oldest and frailest adults are needed to define optimal treatment intensity, monitoring, and functional outcomes.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2026-11-16
DOI
https://doi.org/10.3389/fphar.2026.2001039
Primary Topic
Pharmacology and Obesity Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Incretin-based therapies in older adults: current evidence and clinical considerations

Mojca Jensterle, Andrijana Koceva, Andrej Janež
1 links
Frontiers in Pharmacology
Pharmacology and Obesity Treatment
article

Incretin-based therapies in older adults: current evidence and clinical considerations

Mojca Jensterle, Andrijana Koceva, Andrej Janež
article en

Abstract

Incretin-based therapies have transformed obesity treatment, but evidence in older adults remains limited. Available analyses indicate that weight-loss efficacy is broadly preserved after the age of 65, and no consistent age-specific safety signal has emerged. However, adults aged ≥ 75 years, particularly those with frailty, sarcopenia, malnutrition, or functional impairment, remain underrepresented. Gastrointestinal adverse events may have greater clinical consequences in older adults as reduced intake, dehydration, and medication interactions may compromise physiological reserve. Weight loss also induces loss of lean tissue, although current data do not establish that this routinely translates into sarcopenia or functional decline. Clinical care should focus on net benefit rather than weight reduction alone, incorporating nutritional status, muscle strength, physical function, multimorbidity and polypharmacy. Prospective studies enriched for the oldest and frailest adults are needed to define optimal treatment intensity, monitoring, and functional outcomes.

Frontiers in PharmacologyVol. 17
University of Ljubljana (SI), Ljubljana University Medical Centre (SI), University of Maribor (SI), University Clinical Centre Maribor (SI)
Good health and well-being
Pharmacology and Obesity Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon